Topping the 11th annual list is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.
Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability
4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).
Diversigen Announces Strategic Partnership with Korea-based BioCore
Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with BioCore Co. Ltd., a leading bioanalytical contract research organization, based in Seoul, South Korea.
Diversigen Announces Strategic Partnership With Baylor Miraca
Diversigen, Inc. announces a strategic partnership with Baylor Miraca Genetics Laboratories (BMGL), a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
Dr. George Gunn joins Diversigen Board of Directors
Diversigen, Inc., today announced the appointment of Dr. George Gunn to the company’s Board of Directors. Dr. Gunn is renowned for his successful leadership and contributions to the global animal health and pharmaceutical industries. Until January 2015, Dr. Gunn was Division Head of Novartis Animal Health and a member of the Novartis Executive Committee.
“We believe the name Diversigen encompasses the extensive expertise that we deliver across the entire project life cycle to help our customers understand and harness the vast opportunities rapidly emerging in microbiome research,” according to Joesph F. Petrosino, PhD, Diversigen Founder and Chief Science Officer, as well as Director of the Alkek Center for Metagenomics and Microbiome Research and Associate Professor of Virology and Microbiology at Baylor College of Medicine.
A passionate kiss that lasts more than 10 seconds transfers about 80 million bacteria, researchers say. The evidence, published in the journal Microbiome, comes from 21 couples, ages 17 to 45 who made out for science.
Listen to Remco Kort, a microbiologist at the Netherlands Organisation for Applied Scientific Research in Amsterdam and lead author of the study as he speaks with NPR’s Rob Stein in this recent interview.
“It is provocative to think that we can perhaps donate beneficial microbes by an ‘oral microbiome transplant,’ ” says Joseph Petrosino, Ph.D., Metanome Founder and Chief Scientific Officer and microbiologist at the Baylor College of Medicine.
Dr. Mills said that he is excited about the opportunity to help lead Metanome to the next level in its development. “Metanome is quickly making a name for itself by partnering with innovative pharmaceutical companies and providing best in class metagenomic services and data analytics, all fueled by access to the breadth and depth of microbiome research at Baylor College of Medicine.”
Metanome scientists Joseph F. Petrosino and Nadim J. Ajami co-author a chapter “Toward the Understanding of the Human Virome”, in this newly published book, which expertly describes the latest metagenomic methodologies and best-practices for microbiome studies from sample collection to data analysis for taxonomic, whole shotgun metagenomic, and metatranscriptomic studies.